Pear Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Pear Therapeutics generated cash of -$113,895,000, which is less than the previous year. Cash used in financing activities reached the amount of $2,155,000 last year. Net change in cash is therefore -$121,197,000.
Cash Flow
| 2019 | -36.59M | -40.56M | 12.65M |
|---|---|---|---|
| 2020 | -67.89M | 58.92M | 91.70M |
| 2021 | -109.04M | 2.88M | 164.07M |
| 2022 | -113.89M | -9.45M | 2.15M |
PEAR Cash Flow Statement (2019 – 2022)
| 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|
Cash at beginning of period | 169.97M | 112.06M | 29.32M | 93.82M |
Operating activities | ||||
Net income | -75.49M | -65.14M | -97.02M | -9.33M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||
Depreciation and amortization | 5.70M | 2.25M | 431K | 209K |
Stock-based compensation expense | 13.53M | 3.81M | 9.02M | 1.28M |
| Deferred income tax benefit | 13.53M | 3.81M | 9.02M | 1.28M |
| Changes in operating assets and liabilities: | ||||
Accounts receivable, net | -5.15M | -1.19M | 751K | 862K |
Inventories | 0 | -1.83M | 4.06M | 1.64M |
Accounts payable | 4K | -3.09M | 1.73M | 1.09M |
Cash generated by operating activities | -113.89M | -109.04M | -67.89M | -36.59M |
Investing activities | ||||
Purchases Of Investments | -66.03M | -8.01M | -16.02M | -195.13M |
Investments In Property Plant And Equipment | -3.47M | -4.62M | -3.9M | -281K |
Acquisitions Net | 0 | -1.35M | 0 | 0 |
Cash generated by investing activities | -9.45M | 2.88M | 58.92M | -40.56M |
Financing activities | ||||
Common Stock Issued | 1.79M | 2.05M | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -31.98M | 0 |
Repayments of term debt | 0 | -1M | -17.28M | 0 |
Cash used in financing activities | 2.15M | 164.07M | 91.70M | 12.65M |
Net Change In Cash | -121.19M | 57.91M | 82.73M | -64.50M |
Cash at end of period | 48.78M | 169.97M | 112.06M | 29.32M |
| Data source | Data source |